Zacks: Analysts Expect AC Immune SA (ACIU) Will Announce Quarterly Sales of $4.75 Million

Equities research analysts expect that AC Immune SA (NASDAQ:ACIU) will post sales of $4.75 million for the current quarter, according to Zacks. Two analysts have provided estimates for AC Immune’s earnings. The highest sales estimate is $6.59 million and the lowest is $2.90 million. AC Immune posted sales of $16.64 million during the same quarter last year, which suggests a negative year over year growth rate of 71.5%. The company is scheduled to report its next quarterly earnings results on Tuesday, March 19th.

According to Zacks, analysts expect that AC Immune will report full-year sales of $8.20 million for the current year, with estimates ranging from $3.51 million to $12.39 million. For the next year, analysts anticipate that the firm will report sales of $13.11 million, with estimates ranging from $6.99 million to $19.22 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover AC Immune.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Tuesday, November 13th. The company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.04. AC Immune had a negative net margin of 146.09% and a negative return on equity of 24.14%. The company had revenue of $2.34 million for the quarter, compared to analyst estimates of $1.71 million.

A number of analysts recently weighed in on ACIU shares. Zacks Investment Research raised shares of AC Immune from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research report on Wednesday, November 21st. BidaskClub raised shares of AC Immune from a “hold” rating to a “buy” rating in a research report on Wednesday, November 21st. HC Wainwright set a $18.00 price objective on shares of AC Immune and gave the stock a “buy” rating in a research report on Thursday, August 9th. ValuEngine lowered shares of AC Immune from a “buy” rating to a “hold” rating in a research report on Monday, August 20th. Finally, Leerink Swann started coverage on shares of AC Immune in a research report on Monday, November 12th. They issued an “outperform” rating and a $18.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $15.25.

AC Immune stock opened at $11.12 on Friday. AC Immune has a 1-year low of $7.16 and a 1-year high of $17.40. The stock has a market capitalization of $746.22 million, a P/E ratio of -37.07 and a beta of 1.09.

Large investors have recently modified their holdings of the company. GSA Capital Partners LLP purchased a new position in shares of AC Immune during the third quarter worth approximately $110,000. JPMorgan Chase & Co. purchased a new position in shares of AC Immune during the third quarter worth approximately $142,000. Compagnie Lombard Odier SCmA increased its position in shares of AC Immune by 858.3% during the third quarter. Compagnie Lombard Odier SCmA now owns 33,539 shares of the company’s stock worth $268,000 after acquiring an additional 30,039 shares during the period. Belpointe Asset Management LLC purchased a new position in shares of AC Immune during the third quarter worth approximately $400,000. Finally, Renaissance Technologies LLC increased its position in shares of AC Immune by 131.6% during the third quarter. Renaissance Technologies LLC now owns 52,300 shares of the company’s stock worth $418,000 after acquiring an additional 29,720 shares during the period. 20.04% of the stock is currently owned by institutional investors and hedge funds.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Featured Article: What is a bull market?

Get a free copy of the Zacks research report on AC Immune (ACIU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AC Immune (NASDAQ:ACIU)

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit